메뉴 건너뛰기




Volumn 7, Issue 6, 2017, Pages

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CLINICAL TRIAL; CONVALESCENCE; DISEASE FREE SURVIVAL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; SURVIVAL RATE; VERY ELDERLY;

EID: 85048374598     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2017.49     Document Type: Letter
Times cited : (32)

References (15)
  • 1
    • 84903904015 scopus 로고    scopus 로고
    • Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
    • Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014; 25: 195–200.
    • (2014) Ann Oncol , vol.25 , pp. 195-200
    • Dimopoulos, M.A.1    Delimpasi, S.2    Katodritou, E.3    Vassou, A.4    Kyrtsonis, M.C.5    Repousis, P.6
  • 2
    • 84965050407 scopus 로고    scopus 로고
    • International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
    • Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016; 34: 1544–1557.
    • (2016) J Clin Oncol , vol.34 , pp. 1544-1557
    • Dimopoulos, M.A.1    Sonneveld, P.2    Leung, N.3    Merlini, G.4    Ludwig, H.5    Kastritis, E.6
  • 4
    • 0028824562 scopus 로고
    • Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases
    • Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.
    • (1995) Br J Haematol , vol.91 , pp. 854-859
    • Torra, R.1    Blade, J.2    Cases, A.3    Lopez-Pedret, J.4    Montserrat, E.5    Rozman, C.6
  • 5
    • 0033851432 scopus 로고    scopus 로고
    • Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group
    • Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.
    • (2000) Eur J Haematol , vol.65 , pp. 175-181
    • Knudsen, L.M.1    Hjorth, M.2    Hippe, E.3
  • 6
    • 0025294041 scopus 로고
    • Renal failure in multiple myeloma. Pathogenesis and prognostic implications
    • Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695.
    • (1990) Arch Intern Med , vol.150 , pp. 1693-1695
    • Alexanian, R.1    Barlogie, B.2    Dixon, D.3
  • 7
    • 0032575885 scopus 로고    scopus 로고
    • Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution
    • Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.
    • (1998) Arch Intern Med , vol.158 , pp. 1889-1893
    • Blade, J.1    Fernandez-Llama, P.2    Bosch, F.3    Montoliu, J.4    Lens, X.M.5    Montoto, S.6
  • 8
    • 85014602497 scopus 로고    scopus 로고
    • Evolution in the treatment of multiple myeloma and impact on dialysis inde-pendence: Data from a French cohort from 1999 to 2014
    • Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P et al. Evolution in the treatment of multiple myeloma and impact on dialysis inde-pendence: data from a French cohort from 1999 to 2014. Blood Cancer J 2016; 6: e409.
    • (2016) Blood Cancer J , vol.6 , pp. e409
    • Laforet, M.1    Jourde-Chiche, N.2    Haddad, F.3    Sallee, M.4    Stoppa, A.M.5    Brunet, P.6
  • 9
    • 85020620007 scopus 로고    scopus 로고
    • High cut-off haemodialysis(HCO-HD) does not improve outcomes in myeloma cast nephro-pathy: Results of European trial of Free Light Chain removal extended haemo-dialysis in cast nephropathy (EULITE)
    • Abstract P270
    • Cook M, Hutchison C, Fifer L, Gillmore J, Heyne N, Weisel K et al. High cut-off haemodialysis(HCO-HD) does not improve outcomes in myeloma cast nephro-pathy: results of European trial of Free Light Chain removal extended haemo-dialysis in cast nephropathy (EULITE). EHA 2016; Abstract P270.
    • (2016) EHA
    • Cook, M.1    Hutchison, C.2    Fifer, L.3    Gillmore, J.4    Heyne, N.5    Weisel, K.6
  • 10
    • 85020601456 scopus 로고    scopus 로고
    • Treatment of myeloma cast nephropathy (MCN): A randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Inter-groupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))
    • Bridoux F, Pegourie B, Augeul-Meunier K, Royer B, Joly B, Lamy T et al. Treatment of myeloma cast nephropathy (MCN): a randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Inter-groupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)). Blood 2016; 128: 978–978.
    • (2016) Blood , vol.128 , pp. 978
    • Bridoux, F.1    Pegourie, B.2    Augeul-Meunier, K.3    Royer, B.4    Joly, B.5    Lamy, T.6
  • 12
    • 34547706021 scopus 로고    scopus 로고
    • Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
    • Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546–549.
    • (2007) Haematologica , vol.92 , pp. 546-549
    • Kastritis, E.1    Anagnostopoulos, A.2    Roussou, M.3    Gika, D.4    Matsouka, C.5    Barmparousi, D.6
  • 14
    • 84951020021 scopus 로고    scopus 로고
    • Revised international staging system for multiple myeloma: A report from international myeloma working group
    • Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015; 33: 2863–2869.
    • (2015) J Clin Oncol , vol.33 , pp. 2863-2869
    • Palumbo, A.1    Avet-Loiseau, H.2    Oliva, S.3    Lokhorst, H.M.4    Goldschmidt, H.5    Rosinol, L.6
  • 15
    • 85014448913 scopus 로고    scopus 로고
    • Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma
    • Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E et al. Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma. Hae-matologica 2016; 102: 593–599.
    • (2016) Hae-Matologica , vol.102 , pp. 593-599
    • Kastritis, E.1    Terpos, E.2    Roussou, M.3    Gavriatopoulou, M.4    Migkou, M.5    Eleutherakis-Papaiakovou, E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.